Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMAG AMAG Pharmaceuticals	$13.75	$13.74	$4.41 ▼ $13.80	$477.47M	0.89	950,664 shs	N/A
FULC Fulcrum Therapeutics	$7.39 -2.0%	$7.04	$2.32 ▼ $8.50	$399.74M	2.82	372,330 shs	2.10 million shs
MCRB Seres Therapeutics	$17.45 -3.2%	$16.35	$6.53 ▼ $24.67	$152.77M	0.15	242,295 shs	205,420 shs
NERV Minerva Neurosciences	$2.03 -1.5%	$2.10	$1.15 ▼ $2.87	$14.19M	-0.25	15,530 shs	9,901 shs
PRQR ProQR Therapeutics	$2.10 -4.1%	$2.19	$1.07 ▼ $4.62	$220.95M	0.36	355,946 shs	134,353 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMAG AMAG Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
FULC Fulcrum Therapeutics	0.00%	+5.57%	+13.34%	+5.72%	+114.83%
MCRB Seres Therapeutics	0.00%	+9.68%	-4.75%	+135.81%	-16.90%
NERV Minerva Neurosciences	0.00%	-5.36%	-15.77%	+13.09%	-28.77%
PRQR ProQR Therapeutics	0.00%	-4.11%	-4.98%	+8.81%	+16.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMAG AMAG Pharmaceuticals	$13.75	$13.74	$4.41 ▼ $13.80	$477.47M	0.89	950,664 shs	N/A
FULC Fulcrum Therapeutics	$7.39 -2.0%	$7.04	$2.32 ▼ $8.50	$399.74M	2.82	372,330 shs	2.10 million shs
MCRB Seres Therapeutics	$17.45 -3.2%	$16.35	$6.53 ▼ $24.67	$152.77M	0.15	242,295 shs	205,420 shs
NERV Minerva Neurosciences	$2.03 -1.5%	$2.10	$1.15 ▼ $2.87	$14.19M	-0.25	15,530 shs	9,901 shs
PRQR ProQR Therapeutics	$2.10 -4.1%	$2.19	$1.07 ▼ $4.62	$220.95M	0.36	355,946 shs	134,353 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMAG AMAG Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
FULC Fulcrum Therapeutics	0.00%	+5.57%	+13.34%	+5.72%	+114.83%
MCRB Seres Therapeutics	0.00%	+9.68%	-4.75%	+135.81%	-16.90%
NERV Minerva Neurosciences	0.00%	-5.36%	-15.77%	+13.09%	-28.77%
PRQR ProQR Therapeutics	0.00%	-4.11%	-4.98%	+8.81%	+16.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMAG AMAG Pharmaceuticals	0.00	N/A	N/A	N/A
FULC Fulcrum Therapeutics	3.00	Buy	$9.60	29.91% Upside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	322.16% Upside
NERV Minerva Neurosciences	2.00	Hold	$5.00	146.31% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	280.95% Upside

Current Analyst Ratings Breakdown

Latest PRQR, NERV, MCRB, FULC, and AMAG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	PRQR ProQR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$4.00
7/30/2025	FULC Fulcrum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$4.00 ➝ $5.00
7/29/2025	FULC Fulcrum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $12.00
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$8.00

(Data available from 9/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMAG AMAG Pharmaceuticals	$327.75M	1.46	N/A	N/A	$7.37 per share	1.87
FULC Fulcrum Therapeutics	$80M	5.00	N/A	N/A	$4.51 per share	1.64
MCRB Seres Therapeutics	$126.32M	1.21	N/A	N/A	$1.61 per share	10.84
NERV Minerva Neurosciences	N/A	N/A	$0.21 per share	9.71	($3.67) per share	N/A
PRQR ProQR Therapeutics	$20.46M	10.80	N/A	N/A	$0.91 per share	2.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMAG AMAG Pharmaceuticals	-$466.46M	-$6.88	N/A	76.39	N/A	-74.93%	-16.92%	-5.96%	N/A
FULC Fulcrum Therapeutics	-$9.73M	-$1.22	N/A	N/A	N/A	N/A	-31.05%	-28.96%	11/12/2025 (Estimated)
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-350.16%	-67.69%	11/12/2025 (Estimated)
NERV Minerva Neurosciences	$1.44M	$1.48	1.37	N/A	N/A	N/A	-41.35%	31.37%	11/4/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.04M	-$0.46	N/A	N/A	N/A	-238.52%	-61.25%	-28.13%	11/6/2025 (Estimated)

Latest PRQR, NERV, MCRB, FULC, and AMAG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	NERV Minerva Neurosciences	-$0.95	-$0.43	+$0.52	-$0.43	N/A	N/A
8/7/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	-$0.14	-$0.06	-$0.14	$5.01 million	$4.33 million
8/6/2025	Q2 2025	MCRB Seres Therapeutics	-$2.72	-$2.27	+$0.45	-$2.27	$11.75 million	N/A
7/29/2025	Q2 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMAG AMAG Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMAG AMAG Pharmaceuticals	1.13	1.75	1.45
FULC Fulcrum Therapeutics	N/A	24.42	24.42
MCRB Seres Therapeutics	N/A	1.57	1.57
NERV Minerva Neurosciences	N/A	6.15	6.15
PRQR ProQR Therapeutics	N/A	3.76	3.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMAG AMAG Pharmaceuticals	N/A
FULC Fulcrum Therapeutics	89.83%
MCRB Seres Therapeutics	59.34%
NERV Minerva Neurosciences	34.56%
PRQR ProQR Therapeutics	32.65%

Insider Ownership

Company	Insider Ownership
AMAG AMAG Pharmaceuticals	12.73%
FULC Fulcrum Therapeutics	7.00%
MCRB Seres Therapeutics	4.70%
NERV Minerva Neurosciences	8.60%
PRQR ProQR Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMAG AMAG Pharmaceuticals	440	34.73 million	N/A	Optionable
FULC Fulcrum Therapeutics	100	54.09 million	50.31 million	Optionable
MCRB Seres Therapeutics	330	8.75 million	8.34 million	Optionable
NERV Minerva Neurosciences	9	6.99 million	N/A	Not Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable

PRQR, NERV, MCRB, FULC, and AMAG Headlines

Recent News About These Companies

ProQR Therapeutics N.V. (NASDAQ:PRQR) Sees Significant Increase in Short Interest

September 16, 2025 | marketbeat.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives $8.00 Consensus Price Target from Analysts

September 16, 2025 | americanbankingnews.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Buy" from Analysts

September 15, 2025 | marketbeat.com

ProQR Therapeutics N.V. $PRQR Shares Sold by Adage Capital Partners GP L.L.C.

September 9, 2025 | marketbeat.com

HC Wainwright Expects Lower Earnings for ProQR Therapeutics

August 30, 2025 | marketbeat.com

ProQR Therapeutics N.V. $PRQR Shares Bought by Affinity Asset Advisors LLC

August 28, 2025 | marketbeat.com

1,850,348 Shares in ProQR Therapeutics N.V. $PRQR Purchased by Aberdeen Group plc

August 24, 2025 | marketbeat.com

PRQR | ProQR Therapeutics N.V. Stock Price & News - WSJ

August 12, 2025 | wsj.com

ProQR Announces Second Quarter 2025 Operating and Financial Results

August 7, 2025 | globenewswire.com

ProQR Announces Upcoming Presentation at RNA Editing Summit

July 28, 2025 | globenewswire.com

ProQR Therapeutics price target raised to $5 from $4 at Evercore ISI

July 12, 2025 | msn.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com

July 8, 2025 | investing.com

PRQR - ProQR Therapeutics NV Sustainability - Morningstar

July 3, 2025 | morningstar.comM

PRQR - ProQR Therapeutics NV Key Metrics - Morningstar

July 2, 2025 | morningstar.comM

ProQR Therapeutics NV (PRQR) Stock Forums - Investing.com

June 29, 2025 | investing.com

ProQR Therapeutics N.V. (PRQR) - Yahoo Finance

June 29, 2025 | finance.yahoo.com

ProQR Therapeutics N.V.: ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 27, 2025 | finanznachrichten.de

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 26, 2025 | globenewswire.com

ProQR Therapeutics Reports Q1 2025 Financial Results

June 2, 2025 | tipranks.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year

May 24, 2025 | investing.com

ProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock News

May 13, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR, NERV, MCRB, FULC, and AMAG Company Descriptions

AMAG Pharmaceuticals NASDAQ:AMAG

AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Fulcrum Therapeutics NASDAQ:FULC

$7.39 -0.15 (-1.99%)

Closing price 09/19/2025 04:00 PM Eastern

Extended Trading

$7.54 +0.15 (+2.03%)

As of 09/19/2025 05:30 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Seres Therapeutics NASDAQ:MCRB

$17.45 -0.58 (-3.22%)

Closing price 09/19/2025 04:00 PM Eastern

Extended Trading

$17.15 -0.30 (-1.72%)

As of 09/19/2025 04:10 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Minerva Neurosciences NASDAQ:NERV

$2.03 -0.03 (-1.46%)

Closing price 09/19/2025 04:00 PM Eastern

Extended Trading

$2.00 -0.03 (-1.43%)

As of 09/19/2025 05:16 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

ProQR Therapeutics NASDAQ:PRQR

$2.10 -0.09 (-4.11%)

Closing price 09/19/2025 04:00 PM Eastern

Extended Trading

$2.16 +0.06 (+2.86%)

As of 09/19/2025 06:54 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRQR, NERV, MCRB, FULC, and AMAG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRQR, NERV, MCRB, FULC, and AMAG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRQR, NERV, MCRB, FULC, and AMAG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR, NERV, MCRB, FULC, and AMAG Company Descriptions

AMAG Pharmaceuticals NASDAQ:AMAG

Fulcrum Therapeutics NASDAQ:FULC

Seres Therapeutics NASDAQ:MCRB

Minerva Neurosciences NASDAQ:NERV

ProQR Therapeutics NASDAQ:PRQR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRQR, NERV, MCRB, FULC, and AMAG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRQR, NERV, MCRB, FULC, and AMAG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRQR, NERV, MCRB, FULC, and AMAG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR, NERV, MCRB, FULC, and AMAG Company Descriptions

AMAG Pharmaceuticals NASDAQ:AMAG

Fulcrum Therapeutics NASDAQ:FULC

Seres Therapeutics NASDAQ:MCRB

Minerva Neurosciences NASDAQ:NERV

ProQR Therapeutics NASDAQ:PRQR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools